Clearside Biomedical, Inc. (CLSD)
| Market Cap | 189.20M |
| Revenue (ttm) | 9.83M |
| Net Income (ttm) | -14.19M |
| Shares Out | 46.98M |
| EPS (ttm) | -0.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 1 |
| Last Price | $3.45 |
| Previous Close | $3.31 |
| Change ($) | 0.14 |
| Change (%) | 4.23% |
| Day's Open | 3.45 |
| Day's Range | 3.30 - 3.71 |
| Day's Volume | 490,012 |
| 52-Week Range | 1.10 - 4.53 |
ALPHARETTA, Ga., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and pres...
ALPHARETTA, Ga., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and pres...
ALPHARETTA, Ga., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and pres...
- Proprietary suprachoroidal injection platform demonstrates broad applicability across multiple retinal disorders -
As of late, it has definitely been a great time to be an investor in Clearside Biomedical (CLSD).
Investors need to pay close attention to Clearside Biomedical (CLSD) stock based on the movements in the options market lately.
Does Clearside Biomedical, Inc. (CLSD) have what it takes to be a top stock pick for momentum investors? Let's find out.
ALPHARETTA, Ga., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and pres...
ALPHARETTA, Ga., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and pres...
Clearside Biomedical is aiming to make ocular gene therapy accessible. XIPERE NDA resubmission and potential approval in 2021 triggering a $15 million payment from partner Bausch Health.
Two new breakout stocks for Week 1 of 2021 with better than 10% short-term upside potential. The MDA breakout picks completed 2020 up +73.4% beating the S&P 500 for the 4th consecutive year wi...
ALPHARETTA, Ga., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and pre...
ALPHARETTA, Ga., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and pres...
Clearside Biomedical, Inc.(CLSD) CEO George Lasezkay on Q3 2020 Results - Earnings Call Transcript
- Initiation of Phase 1/2a Trial of CLS-AX ( axitinib injectable suspension ) for Wet Age-Related Macular Degeneration Expected by Year-End 2020 - - Phase 2 Trials Using SCS Microinjector ® On...
ALPHARETTA, Ga., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and pres...
Clearside Biomedical (CLSD) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Presented the most robust aggregate dataset of suprachoroidal clinical injections demonstrating reliability and consistency of procedure Presented the most robust aggregate dataset of supracho...
ALPHARETTA, Ga., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and ...
ALPHARETTA, Ga., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and p...
ALPHARETTA, Ga., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and ...
- New intellectual property covers suprachoroidal administration with therapeutic agents including CLS-AX and XIPERE - - New intellectual property covers suprachoroidal administration with the...
Clearside Biomedical, Inc. (CLSD) CEO George Lasezkay on Q2 2020 Results - Earnings Call Transcript
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 0.00% and -75.47%, respectively, for the quarter ended June 2020.
- IND Accepted by FDA for Suprachoroidal CLS-AX (axitinib injectable suspension) - - Expanded Internal Suprachoroidal Pipeline with Two New Preclinical Programs - - Engaged New Contract Manu...
- Initiation of CLS-AX Phase 1/2a Clinical Trial in Wet AMD Targeted by Year-End 2020 -
ALPHARETTA, Ga., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and pr...
Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
ALPHARETTA, Ga., July 30, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and pr...
Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
ALPHARETTA, Ga., July 27, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and pr...
Clearside Biomedical, Inc. (CLSD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
– Preclinical CLS-AX data demonstrates a potentially long-acting therapy for neovascular age-related macular degeneration –
Clearside Biomedical Inc (CLSD) delivered earnings and revenue surprises of 22.22% and 2.43%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for t...
Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
- Management to Host Webcast and Conference Call Today at 8:30 A.M. ET -
- Pfizer veteran brings global R&D expertise to Board of Directors - - Pfizer veteran brings global R&D expertise to Board of Directors -
ALPHARETTA, Ga., April 09, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and p...
Clearside Biomedical, Inc. (CLSD) CEO George Lasezkay on Q4 2019 Results - Earnings Call Transcript
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -75.00% and -67.06%, respectively, for the quarter ended December 2019.
ALPHARETTA, Ga., March 11, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and p...
– Arctic Vision to Lead Expansion of Novel Approach to Treating Macular Edema Associated with Uveitis in Asia – – Clearside Eligible to Receive Upfront and Milestone Payments and Royalties on...
Clearside Biomedical, Inc. (CLSD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Presentations to Focus on Novel Suprachoroidal Delivery of CLS-AX (axitinib injectable suspension) as a Potential Long-Acting Therapy for Neovascular Age-Related Macular Degeneration Presentat...
As of late, it has definitely been a great time to be an investor in Clearside Biomedical.
Investors need to pay close attention to Clearside Biomedical (CLSD) stock based on the movements in the options market lately.
Clearside Biomedical, Inc. (CLSD) CEO George Lasezkay on Q3 2019 Results - Earnings Call Transcript
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -6.25% and 182.00%, respectively, for the quarter ended September 2019.
ALPHARETTA, Ga., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and p...
XIPERE™ presentations continue to demonstrate the potential value to treat uveitis patients XIPERE™ presentations continue to demonstrate the potential value to treat uveitis patients
About CLSD
Clearside Biomedical, a biopharmaceutical company, develops and delivers treatment that restore and preserve vision for people with serious eye diseases. Its preclinical products include CLS-AX, an axitinib for suprachoroidal injection. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
| Industry Biotechnology | IPO Date Jun 2, 2016 |
| CEO George Lasezkay | Employees 33 |
| Stock Exchange NASDAQ | Ticker Symbol CLSD |
Financial Performance
In 2019, CLSD's revenue was $2.17 million, an increase of 7,143.33% compared to the previous year's $30,000. Losses were -$30.77 million, -62.85% less than in 2018.
Analyst Forecasts
According to 6 analysts, the average rating for CLSD stock is "Buy." The 12-month stock price forecast is 6.38, which is an increase of 84.93% from the latest price.